Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully

Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug... Int Urol Nephrol (2017) 49:1637–1643 DOI 10.1007/s11255-017-1627-6 NEPHROLOGY - ORIGINAL PAPER Fosfomycin for the treatment of drug‑resistant urinary tract infections: potential of an old drug not explored fully 1 1 Vrushali Patwardhan · Sarman Singh Received: 18 January 2017 / Accepted: 19 May 2017 / Published online: 14 June 2017 © Springer Science+Business Media Dordrecht 2017 Abstract Gram-positive isolates [698/707 (96%)] and MRSA [61/69 Introduction Increased emergence of bacterial resistance (88.4%)] were susceptible to fosfomycin. and the limited options of novel antimicrobial agents have Conclusions Fosfomycin showed an excellent in vitro necessitated the reintroduction of some old antimicrobial activity against all urinary pathogens, including the Gram- agents. One such drug is fosfomycin, but its potential has positive or Gram-negative, ESBL and MBL producers. Fos- not been explored fully, especially in India. fomycin should be considered as a highly effective alterna- Aims and objectives To analyze the in vitro activity of fos- tive in treatment UTIs in both adults and pediatric patients. fomycin, against the urinary isolates and to compare it with in vitro activity of other orally administered antimicrobial Keywords Uropathogens · Fosfomycin · EMBL · ESBL agents. Materials and methods This was a prospective observa- tional study conducted http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Urology and Nephrology Springer Journals

Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully

Loading next page...
 
/lp/springer_journal/fosfomycin-for-the-treatment-of-drug-resistant-urinary-tract-ELsUUSPLUS
Publisher
Springer Netherlands
Copyright
Copyright © 2017 by Springer Science+Business Media Dordrecht
Subject
Medicine & Public Health; Nephrology; Urology
ISSN
0301-1623
eISSN
1573-2584
D.O.I.
10.1007/s11255-017-1627-6
Publisher site
See Article on Publisher Site

Abstract

Int Urol Nephrol (2017) 49:1637–1643 DOI 10.1007/s11255-017-1627-6 NEPHROLOGY - ORIGINAL PAPER Fosfomycin for the treatment of drug‑resistant urinary tract infections: potential of an old drug not explored fully 1 1 Vrushali Patwardhan · Sarman Singh Received: 18 January 2017 / Accepted: 19 May 2017 / Published online: 14 June 2017 © Springer Science+Business Media Dordrecht 2017 Abstract Gram-positive isolates [698/707 (96%)] and MRSA [61/69 Introduction Increased emergence of bacterial resistance (88.4%)] were susceptible to fosfomycin. and the limited options of novel antimicrobial agents have Conclusions Fosfomycin showed an excellent in vitro necessitated the reintroduction of some old antimicrobial activity against all urinary pathogens, including the Gram- agents. One such drug is fosfomycin, but its potential has positive or Gram-negative, ESBL and MBL producers. Fos- not been explored fully, especially in India. fomycin should be considered as a highly effective alterna- Aims and objectives To analyze the in vitro activity of fos- tive in treatment UTIs in both adults and pediatric patients. fomycin, against the urinary isolates and to compare it with in vitro activity of other orally administered antimicrobial Keywords Uropathogens · Fosfomycin · EMBL · ESBL agents. Materials and methods This was a prospective observa- tional study conducted

Journal

International Urology and NephrologySpringer Journals

Published: Jun 14, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off